The invention relates to the use of substances as a fundamental constituent in wound healing agents. The invention is characterised in that said substances bond to either IAP and/or integrin .alpha..sub.v.beta..sub.3 and/or thrombuspondin-1 in such a way that the bond between thrumbospondin-1 and IAP and/or integrin .alpha..sub.v.beta..sub.3 is inhibited.